{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:03:49Z","timestamp":1782846229817,"version":"3.54.5"},"reference-count":25,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The proinflammatory cytokine interleukin 6 (IL-6) contributes to pancreatic tumorigenesis by activating the Janus kinase (JAK)\u2013signal transducer and activator of transcription 3 (STAT3) signaling cascade. Targeting the IL-6\/glycoprotein 130 (GP130)\/JAK\/STAT3 axis may therefore represent a promising therapeutic approach for pancreatic adenocarcinoma.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n This study investigates the activation of the IL-6\/GP130\/JAK\/STAT3 pathway in archived biopsy samples from patients with pancreatic adenocarcinoma, quantifying its expression in both tumor and stromal compartments. In addition, potential associations between pathway activation and clinical outcomes are explored, including tumor stage, patient survival, and metabolic parameters such as diabetes, use of oral antidiabetic drugs, insulin therapy, and hemoglobin A\n 1c<\/jats:sub>\n levels.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We will conduct a retrospective cross-sectional analysis of patients with pancreatic adenocarcinoma treated at the Cantonal Hospital of Fribourg, Switzerland, between 2010 and 2025. Eligible cases are identified through tumor board records. Archived pathology specimens will be immunostained using a phospho-STAT3 antibody to assess GP130 receptor activation. The percentage of positively stained cells will be quantified separately for tumor tissue, stroma, and adjacent normal tissue using QPath software. Sample size calculations are based on the assumption that patients with higher IL-6 pathway activation have poorer prognoses. Detecting a 5% difference in activation requires 84 patients per group for 90% power or 104 per group for 95% power. Diabetes will be analyzed as a dichotomous variable, while IL-6\/GP130\/JAK\/STAT3 activation will be treated as a continuous variable. Descriptive statistics will summarize pathway activation and clinical variables. Mean differences between groups will be compared, and survival outcomes will be evaluated using Cox proportional hazards models. Hazard ratios will be calculated for all metabolic parameters to assess potential associations between pathway activation and diabetes. All analyses will include 95% CIs, with missing data reported transparently.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This project is supported by a research grant from the Cantonal Hospital of Fribourg (HFR 2\/2021 and 4\/2022). It was approved by the Ethics Committee of Bern, Switzerland (project 2024\u201001215). As of October 12, 2025, clinical records from 150 patients have been identified. Screening of additional patient records from 2024 to 2025 is ongoing.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study represents one of the first translational investigations of IL-6\/GP130\/JAK\/STAT3 signaling in pancreatic adenocarcinoma. By correlating molecular pathway activation with clinical and metabolic features, it will provide new insights into disease heterogeneity and support the development of personalized, pathway-targeted therapeutic strategies.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/76811","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T20:21:03Z","timestamp":1765830063000},"page":"e76811-e76811","source":"Crossref","is-referenced-by-count":3,"title":["IL-6\/GP130\/JAK\/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical Features: Protocol for a Retrospective Cross-Sectional Study"],"prefix":"10.2196","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-6829","authenticated-orcid":false,"given":"Claudia","family":"Mellenthin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1734-5353","authenticated-orcid":false,"given":"Fabien","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4311-4900","authenticated-orcid":false,"given":"Lucie","family":"Vignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-6964","authenticated-orcid":false,"given":"Sarah","family":"Peisl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2846-8691","authenticated-orcid":false,"given":"Rita","family":"Vesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0554-2402","authenticated-orcid":false,"given":"Irene","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-6464","authenticated-orcid":false,"given":"Carmen","family":"Gonelle-Gispert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9628-691X","authenticated-orcid":false,"given":"Cornelia","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-6953","authenticated-orcid":false,"given":"Michel","family":"Adamina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2572-7487","authenticated-orcid":false,"given":"Leo Hans","family":"B\u00fchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"1","key":"R1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01613-x","article-title":"Consensus, debate, and prospective on pancreatic cancer treatments","volume":"17","author":"Wang","journal-title":"J Hematol Oncol"},{"issue":"9293","key":"R2","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/s0140-6736(01)06651-x","article-title":"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial","volume":"358","author":"Neoptolemos","journal-title":"Lancet"},{"issue":"10","key":"R3","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Neoptolemos","journal-title":"JAMA"},{"issue":"10073","key":"R4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","journal-title":"Lancet"},{"issue":"2","key":"R5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"R6","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61061076","article-title":"Improving outcomes in pancreatic adenocarcinoma: a systematic review of immunotherapy in multimodal treatment","volume":"61","author":"Borz","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"R7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.seminoncol.2014.12.002","article-title":"Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma","volume":"42","author":"Yeo","journal-title":"Semin Oncol"},{"key":"R8","unstructured":"Cirillo P Feller A Ho\u0161ek M et al, editors. Schweizerischer Krebsbericht 2021: Stand Und Entwicklungen. Bundesamt f\u00fcr Statistik; ISBN: 9783303143339"},{"issue":"8","key":"R9","doi-asserted-by":"publisher","first-page":"116010","DOI":"10.1016\/j.celrep.2025.116010","article-title":"A STAT3\/integrin axis accelerates pancreatic cancer initiation and progression","volume":"44","author":"Campos","journal-title":"Cell Rep"},{"issue":"4","key":"R10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ccr.2011.03.009","article-title":"Stat3\/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer","volume":"19","author":"Lesina","journal-title":"Cancer Cell"},{"issue":"3","key":"R11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","journal-title":"J Exp Med"},{"issue":"3_suppl","key":"R12","doi-asserted-by":"publisher","first-page":"TPS713","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS713","article-title":"A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC)","volume":"42","author":"Hosein","journal-title":"J Clin Oncol"},{"issue":"11","key":"R13","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-15-0921","article-title":"Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer therapy","volume":"15","author":"Wu","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"R14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2174\/1568009618666180430123939","article-title":"Blocking IL-6\/GP130 signaling inhibits cell viability\/proliferation, glycolysis, and colony forming activity in human pancreatic cancer cells","volume":"19","author":"Chen","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"R15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00432-022-04518-9","article-title":"Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144","volume":"149","author":"Pozios","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6651","key":"R16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/39335","article-title":"Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function","volume":"389","author":"Uysal","journal-title":"Nature New Biol"},{"issue":"7121","key":"R17","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","journal-title":"Nature New Biol"},{"issue":"2","key":"R18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/s0009-8981(98)00125-9","article-title":"Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancer","volume":"277","author":"Fogar","journal-title":"Clin Chim Acta"},{"issue":"11","key":"R19","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1194\/jlr.M075655","article-title":"Blocking gp130 signaling suppresses autotaxin expression in adipocytes and improves insulin sensitivity in diet-induced obesity","volume":"58","author":"Sun","journal-title":"J Lipid Res"},{"issue":"6","key":"R20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190450","article-title":"Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia","volume":"218","author":"Rupert","journal-title":"J Exp Med"},{"issue":"24","key":"R21","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1002\/cam4.4823","article-title":"Interleukin 6\/gp130 axis promotes neural invasion in pancreatic cancer","volume":"11","author":"Suzuki","journal-title":"Cancer Med"},{"issue":"6","key":"R22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252397","article-title":"Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: a systematic review of clinical and preclinical literature","volume":"16","author":"Peisl","journal-title":"PLoS ONE"},{"issue":"5","key":"R23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.hoc.2022.07.001","article-title":"The interplay among pancreatic cancer, cachexia, body composition, and diabetes","volume":"36","author":"Dunne","journal-title":"Hematol Oncol Clin North Am"},{"key":"R24","unstructured":"Sample size calculation. MedCalc. URL: https:\/\/www.medcalc.org\/en\/calc\/sample-size-comparison-of-means.php [Accessed 02-12-2025]"},{"key":"R25","unstructured":"Federal Act on Research Involving Human Beings: Art 34 absence of informed consent. Fedlex Federal Law. Sep 30, 2011. URL: https:\/\/www.fedlex.admin.ch\/eli\/cc\/2013\/617\/en#art_34 [Accessed 02-12-2025]"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2025\/1\/e76811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:08:40Z","timestamp":1782842920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2025\/1\/e76811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":25,"URL":"https:\/\/doi.org\/10.2196\/76811","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"v14i1e76811"}}